GSK has confirmed it will discontinue Flolan, a drug used to treat pulmonary arterial hypertension, in the UK from 2028 — having already pulled it from the US (see our article on this topic here), and other markets. Around 150 UK patients, including children, currently rely on the drug. With production ending in April 2028 and existing stock lasting through summer 2028, specialist centres have roughly two years to transition patients to alternatives, such as Veletri (epoprostenol by Janssen-Cilag), which is compatible across formulations. The UK pulmonary hypertension association PHA UK and specialist centres lobbied GSK to reconsider. Dr Iain Armstrong, PHA UK Chair, reassured patients that stock is secure for now and that affected individuals will be contacted directly by their care teams.
Photo credit: P HA UK Flolan training resources